|
Accession number;01A0256092
|
| Title;A Case of Chronic Renal Failure who Suffered from Hyperkalemia after Administration of Candesartan Cilexetil. |
| Author;
SAITO MAKOTO
(Akashi National Hospital)
ISHIDA YOSHIHIRO
(Akashi National Hospital)
OTA KOJI
(Akashi National Hospital)
HASHIMOTO AKINORI
(Yurinokinaika(akashishi))
MORIMOTO SHIGEFUMI
(Osaka National Hospital)
IWAI AKIHIRO
(Akashi National Hospital)
|
Journal Title;Japanese Journal of Hospital Pharmacy
|
Journal Code:Y0888A
|
ISSN:0389-9098
|
|
VOL.27;NO.1;PAGE.82-88(2001)
|
| Figure&Table&Reference;FIG.3, TBL.2, REF.32 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;A 71-year-old woman had been treated for chronic renal failure (CRF), hypertension and chronic bronchitis at a local clinic since 1999. Her blood pressure had been successfully controlled by arotinolol hydrochloride. In May 2000, however, her blood pressure became poorly controlled and subsequently, the administration of 8 mg/day of candesartan cilexetil was started but proved to be ineffective. As a result, her blood pressure further increased to 200/140mmHg while the serum potassium (K) level reached 7.5mEq/L. She was then hospitalized in our department. Calcium polystyrene sulfonate (CPS) was started in place of candesartan cilexetil for the treatment of hyperkalemia. Her serum K level decreased to 3.0.mEq/L after 1 week with stabilized values of around 3.6mEq/L even after the withdrawal of CPS. Probably due to her basic disease of CRF, urea nitrogen (BUN) increased to 72.7mg/dL, serum creatinine (Scr) to 3.60mg/dL and K to 7.6mEq/L 2 months after the initiation of candesartan cilexetil. Since her renal function recovered after the withdrawal of this drug and the serum K levels decreased to within the normal range, an acute exacerbation of CRF complicated with hyperkalemia due to candesartan cilexetil was finally diagnosed. When an angiotensin II receptor antagonist is administered in patients with renal failure, doctors should carefully monitor for possible changes in the BUN and Scr in addition to a closely observing the serum K levels. (author abst.) |
|
|
|
Related Articles;
|
